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Subcellular compartmentalisation of copper, iron,
manganese, and zinc in the Parkinson’s disease
brain†
Sian Genoud, a Blaine R. Roberts,b Adam P. Gunn,b Glenda M. Halliday,acd
Simon J. G. Lewis,aef Helen J. Ball,g Dominic J. Hare *bhi and Kay L. Double*a
Elevated iron and decreased copper levels are cardinal features of the degenerating substantia nigra pars
compacta in the Parkinson’s disease brain. Both of these redox-active metals, and fellow transition metals
manganese and zinc, are found at high concentrations within the midbrain and participate in a range of
unique biological reactions. We examined the total metal content and cellular compartmentalisation of
manganese, iron, copper and zinc in the degenerating substantia nigra, disease-affected but non-
degenerating fusiform gyrus, and unaffected occipital cortex in the post mortem Parkinson’s disease brain
compared with age-matched controls. An expected increase in iron and a decrease in copper concentration
was isolated to the soluble cellular fraction, encompassing both interstitial and cytosolic metals and metal-
binding proteins, rather than the membrane-associated or insoluble fractions. Manganese and zinc levels did
not differ between experimental groups. Altered Fe and Cu levels were unrelated to Braak pathological
staging in our cases of late-stage (Braak stage V and VI) disease. The data supports our hypothesis that
regional alterations in Fe and Cu, and in proteins that utilise these metals, contribute to the regional
selectively of neuronal vulnerability in this disorder.
Introduction
The brain contains some of the highest concentrations of iron
(Fe), copper (Cu), zinc (Zn) and manganese (Mn) in the human
body.1 These metals are responsible for numerous cellular
functions including synaptic transmission, myelinogenesis,
energy production and regulation of oxidative stress. Many
of these biochemical processes rely on metals for transfer of
electrons via redox chemistry, neuronal excitation, protein
structure and enzymatic function.2 Alterations in the levels
and distribution of these transition metals are consistently
reported in the Parkinson’s disease brain,3,4 with the best
documented change being elevated levels of Fe in the substantia
nigra pars compacta (SNc). Abnormal deposition of Fe in the
Parkinson’s disease brain was first reported in 1924;5 since then
numerous studies have identified significantly increased Fe
levels within vulnerable brain regions in this disorder beyond
those observed in healthy aged-matched brains.6,7
Additionally, a concomitant decrease in Cu concentration
has also been reported in degenerating regions of the Parkinson’s
disease brain,8,9 while data regarding Zn levels are conflicting.3,10
Occupational exposure to Mn alone has been demonstrated to
cause parkinsonism,11 highlighting the necessity for tight Mn
regulation in the brain.
To date, most studies have described regional alterations in
total metal levels (typically Fe) in whole tissue samples.3,6,12,13
While such studies are useful to identify the neuroanatomical
location of changes in specific metals, alterations at the
cellular and subcellular level in the Parkinson’s disease
brain are less well understood. Determining the cellular
compartment in which these changes occur may aid in deter-
mining the underlying cause of these alterations, and the
pathological effects subsequently produced in their subcellular
environment.
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In this study, we examined the subcellular compartmentalisation
of Mn, Fe, Cu and Zn in three regions of the Parkinson’s
disease brain displaying varying degrees of neurodegeneration
and proteinopathology. We separated tissue samples into three
fractions representing the ‘soluble’, ‘membrane-associated’
and ‘insoluble’ tissue components respectively, to identify the
specific cellular compartment in which metal alterations are
most marked. We also examined whether total metal levels
were altered according to late-stage Braak pathology.
Experimental
Ethics, consent and permissions
Human ethics for this study was granted by the University of Sydney
(ID: 2015/202) and the University of Melbourne (ID: 1136882).
Human brain tissue
In total, fresh frozen human post-mortem brain tissue was obtained
from 13 Parkinson’s disease (PD) subjects and 11 age-matched
controls (Ctrl). Three specific regions were analyzed: substantia
nigra (SN; encompassing both pars reticulata and pars compacta
regions; nPD = 9, nCtrl = 8), fusiform gyrus (FUS; nPD = 9, nCtrl = 8) and
occipital cortex (OCx; nPD = 11, nCtrl = 11) were obtained from the
New SouthWales and Sydney Brain Banks. Demographic details for
these cases are shown in Table 1. All Parkinson’s disease cases were
receiving levodopa at the time of death; other anti-parkinsonian
medications prescribed (n = 1 case per medication) were a
COMT inhibitor, a MAO inhibitor, a drug trial of Sarizotan
(a 5-HT1A agonist and D2 dopamine receptor antagonist), and a
dopamine agonist.
Tissue preparation
Tissue preparation was adapted from our previously published
methods.14–17 Tissue samples (11.6–22.5 mg wet weight) were
homogenised with a hand-held dounce (Omni BioMasher,
Georgia, USA) in 3 tissue weight of Tris buffered saline
(TBS: 50 mM Tris; 150 mM NaCl; pH 8.0) containing EDTA free
protease inhibitors (Roche, NSW, Australia). Samples were
centrifuged at 16 000g for 15 min at 4 1C before the supernatant
fraction was collected and stored at 80 1C. This was termed
the ‘soluble fraction’, and represented all cytosolic proteins and
the interstitium. The remaining tissue pellet was resuspended
in 3 tissue weight of urea buffer (7 M urea; 2 M thiourea, 4%
3-[(3-cholamindopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS); 30 mM Bicine; pH 8.5; Sigma, NSW, Australia) and
centrifuged 16000g for 30 min at 4 1C and the resultant super-
natant was collected and stored at 80 1C. This was termed
the ‘membrane fraction’, representing both membrane-bound
proteins and those encased within cellular organelles. The final
pellet was resuspended in 3 tissue weight of 70% formic acid
overnight before being centrifuged at 16 000g for 30 min and
the resultant supernatant collected and stored at 80 1C. This
was termed the ‘insoluble fraction’, and represented all material
not previously extracted. No observable material remained follow-
ing the final preparation step.
Inductively coupled plasma-mass spectrometry (ICP-MS)
ICP-MS analysis was performed according methods previously
reported.18 Each fraction was randomised before being thawed
on ice and diluted 1 : 20 with 1% HNO3 (v/v; Suprapur grade,
Merk Millipore, VIC, Australia) prior to analysis. Total metal
Table 1 Demographic details for experimental tissue. PD = Parkinson’s disease; PMI = post-mortem interval; SEM = standard error of mean; NA = not
available
Case Age Sex Disease duration Primary cause of death Tissue pH Braak staging of PD PMI
PD1 82 M 5 Cardiorespiratory failure 6.72 V NA
PD2 82 F 15 Cerebrovascular accident 6.95 V NA
PD3 83 F 14 Pneumonia 6.69 V 7
PD4 69 M 17 Bronchopneumonia 5.99 V NA
PD5 90 M 7 Respiratory failure 6.25 V NA
PD6 85 F 17 Cerebrovascular accident 6.58 V 26
PD7 74 M 8 Cerebrovascular accident 5.86 VI NA
PD8 83 F 14 Cardiorespiratory failure 6.2 V 32
PD9 79 M 17 Septicaemia 6.7 VI 42
PD10 88 M 23 Cardiorespiratory failure 6.6 V 5
PD11 82 M 22 Cardiorespiratory failure 6.4 VI 19
PD12 82 M 8 Cardiorespiratory failure 6.3 VI 22
PD13 77 M 15 Aspiration pneumonia 6.4 V 15
Mean (SEM) 81.23 (2.36) 9M : 4F 14 (2.37) — 6.43 (0.56) 9V : 4VI 21 (3.52)
Ctrl1 85 F — Pneumonia 6.4 — 23
Ctrl2 79 M — Pulmonary embolism 6.7 — 8
Ctrl3 84 F — Cardiorespiratory failure 6.5 — 6
Ctrl4 89 F — Metastatic adenocarcinoma 6 — 23
Ctrl5 91 M — Cardiorespiratory failure 5.9 — 13
Ctrl6 89 M — Cardiorespiratory failure 6.1 — 33
Ctrl7 102 F — Acute renal failure 5.92 — NA
Ctrl8 89 M — Cardiorespiratory failure 6.7 — 22
Ctrl9 88 F — Cardiorespiratory failure 6.2 — 31
Ctrl10 49 M — Cardiorespiratory failure 6.5 — 47
Ctrl11 41 M — Cardiorespiratory failure 7 — 48
Mean (SEM) 80.55 (4.30) 6M : 5F — 6.36 (0.60) — 25.4 (3.82)
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levels in each fraction were measured using an Agilent
Technologies 7700 ICP-MS system with a Teflon MiraMist
concentric nebuliser and Scott-type double-pass spray chamber
(Glass Expansion, VIC, Australia). Helium (3 mL min1) was
used as a collision gas for removal of polyatomic interferences.
Measured mass-to-charge (m/z) ratios were 55 (Mn), 56 (Fe),
63 (Cu) and 64 (Zn). External calibration was performed using
multi-element standards (Sigma) diluted in 1% HNO3 and
yttrium (Y; m/z = 89; Accustandard, Connecticut, USA) was used
as reference element via online introduction with a Teflon
T-piece.
Statistical analysis
Statistical analyses were performed using Prism v6.0h (GraphPad,
California, USA) for absolute metal levels, and SPSS v22.0 (IBM),
and CoDaPack for compositional data.19 A Student’s two-tailed
t-test was performed to confirm age-matching, and a chi-squared
test for sex-matching and comparing Braak stage. Tissue samples
were background corrected according to their respective buffers,
adjusted for dilution factors and standardised against original
wet sample weights to obtain concentrations in microgram per
gram (mg g1) of wet tissue weight. Samples below instrument
limit of detection were excluded from analysis.20 Outliers were
identified using the combined robust regression and outlier
removal (ROUT) method with a maximum false discovery rate
of 5%.21 Total metal levels were calculated as the sum of the
metal content in each fraction. Metal concentrations in each
fraction for control and Parkinson’s disease groups were compared
using one-way analysis of variance (ANOVA) followed by Sidak post
hoc correction for multiple comparisons, or a Student’s two-tailed
t-test, as noted in the results. For analysis of metal distribution
within fractions between control and Parkinson’s disease groups,
centered-transformations22 were performed in CoDaPack and the
subsequent compositional data was compared using multi-variate
ANOVA in SPSS. All charts were drawn using Prism. A significant
difference was defined as p o 0.05.
Results
Regional distribution of total metal levels in the healthy and
diseases substantia nigra, occipital cortex and fusiform gyrus
Copper concentrations were regionally varied in the healthy
brain with significantly higher levels of Cu in the healthy SN
compared with the OCx and FUS (+153% vs. OCx, p o 0.01;
+233% vs. FUS, p o 0.001; one-way ANOVA; Fig. 1a). The
concentration of Cu in the Parkinson’s disease SN was approxi-
mately half that of control SN (54%, p o 0.05; Student’s two-
tailed t-test), resulting in the significant difference between
nigral Cu concentration and that in the OCx and FUS observed
in the healthy brain being absent in Parkinson’s disease tissue.
As expected, Fe was significantly higher in the healthy SN
compared with FUS (+106%, p o 0.05) and OCx (+61%, p o
0.05; Fig. 1b). In Parkinson’s disease brain, this greater concen-
tration of nigral Fe was more pronounced, with nigral concen-
trations representing more than twice (+210%) that of the
Parkinson’s disease OCx (p o 0.001) and three times (+338%)
that of the Parkinson’s disease FUS (p o 0.001; all one-way
ANOVA), reflecting an accumulation of Fe within the Parkinson’s
disease SN (+105% vs. control SN, po 0.05; Student’s two-tailed
t-test). Both the Parkinson’s disease OCx and FUS did not show
significant changes in Fe concentration when compared to
healthy controls. Zinc levels were unaltered in the Parkinson’s
disease brain in the three regions analysed, though the control
OCx contained less Zn than both the healthy FUS (24%,
p o 0.01) and SN (22%, p o 0.01; one-way ANOVA; Fig. 1c).
Manganese concentrations were significantly higher in both
healthy and diseased SN, compared with the FUS (+40%, po 0.01)
and OCx (+32%, po 0.01; Fig. 1d). Like Cu and Fe, Mn was more
Fig. 1 Biometal distribution in the occipital cortex (OCx) fusiform gyrus
(FUS) and substantia nigra (SN) of healthy aged controls and Parkinson’s
disease. (a) The concentration of Cu in control tissue was highest in the SN,
though in the Parkinson’s disease brain Cu concentrations decreased to
levels equivalent to that in the control SN. (b) In control brains, the
concentration of Fe in the SN was also significantly higher than the
FUS and OCx regions. Iron concentrations were further elevated in
the Parkinson’s disease SN. (c) Zinc concentrations were lowest in the OCx,
and (d) Mn was highest within the SN. Neither Zn or Mn were altered in the
Parkinson’s disease OCx, FUS or SN. * po 0.05, ** po 0.01, *** po 0.001
(vs. control regions); # p o 0.05, ### p o 0.001 (control vs. Parkinson’s
disease SN). All concentrations are mg g1 wet weight of tissue.
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concentrated in the healthy SN than the OCx (+38%, po 0.01) and
FUS (+49%, po 0.01; one-way ANOVA; Fig. S1b, ESI†), though no
changes were observed within regions according to disease state.
Transition metal alterations in cellular compartments of the
Parkinson’s disease substantia nigra
In the Parkinson’s disease SN, the decreased Cu concentration
was confined to the soluble faction (53%; p o 0.01; Fig. 2a).
No detectable Cu was observed in the insoluble fraction in
control brains, but was detected in four of seven of the
Parkinson’s disease SN samples. Similarly, in this region, we
observed elevations in total Fe levels in the Parkinson’s disease
SN that were also attributable to the soluble fraction (+124%,
po 0.01; Fig. 2b). Although total zinc levels were unchanged in
the Parkinson’s disease SN, the membrane-associated fraction
exhibited a significant decrease in this metal confined to this
brain region (34%; p o 0.01; Fig. 2c; Student’s two-tailed
t-tests). Manganese levels did not differ in any fraction between
controls and Parkinson’s disease tissue (Fig. 2d).
The percentage distribution of Cu, Fe, Zn and Mn (Table 2)
in the insoluble, membrane-associated and soluble fraction
was not altered in any brain region between the healthy aged-
control and Parkinson’s disease brain. This suggests that intrinsic
metal dyshomeostasis (i.e. decreased Cu and increased Fe levels)
is not merely a redistribution of available metals, but instead
remains distributed equivalently, with only absolute levels
markedly altered in the Parkinson’s disease SN.
Are altered metal levels in the Parkinson’s disease substantia
nigra related to late Braak staging?
All cases assessed were late-stage Parkinson’s disease, and at
post mortem all were classified as either Braak stage V and four
stage VI, per the established pathological criteria.23 No signifi-
cant difference in total metal levels were observed in any of
Parkinson’s disease tissue from three regions assessed, other
than a slight, non-significant decrease in Fe levels in the FUS
(12%, p = 0.055) (Fig. S2, ESI†). A significantly higher Fe
concentration in the membrane fraction of the SN (+392%;
p o 0.05), and lower Fe concentration in the soluble phase of
the OCx (31%; po 0.01; Fig. 3), was observed in stage VI cases
compared to stage V, though the small sample size and large
variance within the SN suggests these data should be inter-
preted with caution (see Discussion).
Discussion
The regions selected in this study represent three distinct
pathological states in the Parkinson’s disease brain. The SN
is the primary site of dopaminergic neurodegeneration which
results in the clinical movement disorder.24 The dopaminergic
FUS displays synucleinopathy and atrophy25 and is associated
with visual hallucinations and Parkinson’s disease with dementia,
albeit in the absence of neurodegeneration.26 Finally, the OCx
represents an ‘internal control’, in that this region exhibit neither
Lewy pathology nor degeneration in Parkinson’s disease.
The region-specific distribution of total Cu and Fe in the
three measured regions of the healthy brain we report here
was consistent with previous reports.27–29 In the Parkinson’s
disease brain, significant differences in metal levels were
confined to the SN, specifically a decrease in total Cu and
increase in total Fe. Our group has previously reported a 45%
change in total SN Cu levels,8 while others have reported
similar decreases (51% by Ayton et al.30 and 34 to 45% in
Dexter et al.’s landmark study from 198931). Increased nigal Fe
is a well-established feature of Parkinson’s disease from numerous
observational studies, and was further supported by a recent meta-
analysis of these reports.7
Fig. 2 Within both the Parkinson’s disease and control SN, the majority of
(a) Cu, (b) Fe, and (c) Zn was present in the soluble fraction, followed by the
membrane and insoluble fractions, respectively. (d) For Mn, equivalent
amounts were distributed between the soluble and membrane-bound
fractions. In the Parkinson’s disease SN, the observed reduction in total Cu
and increase in total Fe are confined to the soluble fraction, and a decrease
in Zn within the membrane-associated fraction was also observed,
although total Zn levels were not altered. ## p o 0.01, (control vs.
Parkinson’s disease). All concentrations are mg g1 wet weight of tissue.
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For the first time, we have isolated these changes to the
‘soluble’ cellular fraction, which represents the interstitium
and cytoplasm.17 Within this fraction are aqueous proteins
including antioxidant enzymes, as well as free metals present
in the tissue. Membrane-associated metal–protein complexes
likely comprises of protein channels and pumps involved in
transfer of metals across cell plasma membrane, and metals
found within membrane-bound organelles. Despite moderate
metal concentrations in the membrane-associated fractions
(B35% total Fe, B20% total Cu and B45% total Zn; Table 2),
similar changes in Cu and Fe observed in the soluble fraction
were not observed. Metal–protein interactions for the purpose of
transport across the plasma membrane or directed transport
within the cells are likely to be transient however, and thus only
a small proportion of membrane-associated transport proteins
are likely to have been metal-bound at the time of extraction.
A more stable pool of metals may be represented by plasma
bound organelles such as mitochondria, which internalise Fe,
Cu, Mn and Zn for both specific biological function or the
synthesis of metalloproteins such as Fe–sulfur complexes or
cytochrome c oxidase. Although mitochondrial dysfunction,
and resulting effects on metal levels, are proposed to contribute
to neuronal death in Parkinson’s disease,32 the fractionation
technique used here may have masked subtle changes in mito-
chondrial metal levels and specific isolation of mitochondria from
other membrane-encapsulated metals in Parkinson’s disease and
control samples would be required.
The purpose of the current study was to establish the
specific subcellular compartments in which known alterations
in biometals occur. In doing so, we can then narrow the scope
of future proteomic studies targeting these specific subcellular
compartments using high-throughput shotgun proteomics
methods,33 which are currently underway in our laboratory.
In addition, as both a-synuclein and SOD1 are demonstrated to
aggregate in Parkinson’s disease,34 determining the subcellular
fraction where these metal changes occur allows us to then
identify whether these alterations are associated with the
soluble forms of these proteins, or the aggregated form which
would reside in the insoluble fraction.
The insoluble component of SN homogenates represented
only a small proportion of total metal levels and we observed no
changes in metals in this fraction in any brain region. Within
the healthy SN, the insoluble fraction is likely to comprise of
the insoluble macromolecules neuromelanin and lipofuscin,
Table 2 Percentage distribution of Cu, Fe, Zn and Mn in insoluble, membrane-bound and soluble fractions of control and Parkinson’s disease brain.
All data mean  1SD
OCx FUS SN
Control PD Control PD Control PD
Cu
Insoluble 0.66  1.57 0.16  0.54 40.01 40.01 40.01 2.04  5.30
Membrane 21.41  7.88 19.92  9.78 20.49  3.93 22.13  5.56 14.94  4.97 11.14  5.63
Soluble 77.93  7.28 79.92  9.67 79.51  3.93 77.87  5.56 85.06  4.97 86.82  7.15
Fe
Insoluble 5.10  3.48 6.16  2.97 3.64  3.12 3.48  2.52 5.60  3.71 6.50  3.55
Membrane 36.60  12.68 35.04  12.16 44.56  8.31 41.13  4.39 37.93  8.48 26.56  14.32
Soluble 58.30  10.23 58.79  12.36 51.80  6.50 55.40  4.89 56.47  8.89 66.94  14.44
Zn
Insoluble 7.16  3.78 6.47  2.08 7.37  3.95 6.66  3.46 4.45  1.20 7.33  3.66
Membrane 43.19  7.85 44.34  10.02 48.24  4.43 51.83  4.01 40.40  4.69 29.96  6.62
Soluble 49.65  5.63 49.20  9.58 44.39  5.46 41.51  2.97 55.15  5.16 62.71  4.41
Mn
Insoluble 2.24  2.55 6.47  6.67 2.48  3.71 2.22  2.39 2.46  3.37 4.49  2.80
Membrane 45.05  12.58 44.83  17.92 54.13  7.49 51.67  5.22 44.71  4.03 38.73  14.37
Soluble 52.71  11.72 48.70  15.65 43.39  5.20 46.12  4.85 52.83  4.46 56.77  12.37
Fig. 3 Concentration of (a) Cu, (b) Fe, (c) Zn, (d) and Mn in cellular
fractions according to Braak staging in the Parkinson’s disease OCx, FUS
and SN. Only Fe shows any significant change in concentration between
Braak stage V and VI, with a decrease in the soluble fraction of OCx and
increase in the membrane-bound fraction in the SN in stage VI. # po 0.05;
## p o 0.01. I = insoluble, M = membrane, S = soluble.
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cellular pigments which accumulate in the aging human
brain35 and associate with metals, including Fe, Cu, Zn and
Mn.28,29,35,36 These pigments are highly abundant in the aged
human brain, for example neuromelanin fills almost 50% of
the volume of SN dopaminergic soma in individuals in their
eighth decade of life.37 Using in situ subcellular chemical
imaging, we have previously reported increased Fe and
decreased Cu associated with neuromelanin in the SNc neurons
from the Parkinson’s disease brain,8 although here these
changes may have been obscured by the presence of other
equally abundant, but not disease-related, metal-binding
biomolecules, such as lipofuscin, in this tissue fraction. The
insoluble fraction of the Parkinson’s disease SN is also likely
to include a smaller proportion by mass of small insoluble
proteinaceous deposits, including Lewy bodies24 and SOD1
aggregates.34 While metals have been suggested to induce
a-synuclein oligomerisation and aggregation in vitro,38 it is
unclear whether Lewy bodies retain metal ions. We recently
demonstrated that SOD1 aggregates recently identified in
Parkinson’s disease share pathological similarities with the
deposited protein in familial amyotrophic lateral sclerosis
spinal cord and SN,34 and this class of aggregate has been
shown to be deficient in Cu.39 The different populations of
insoluble protein aggregates in degenerating regions of the
Parkinson’s disease brain may thus display metal associations
that differ from that in the normal soluble protein, a hypothesis
that could be tested using, for example, biochemical imaging
analysis at the single aggregate level.
The disease-affected, but non-degenerating, FUS exhibited
no evidence of perturbed metal levels supporting the hypothesis
that metal dyshomeostasis, and associated oxidative stress, are
restricted to specific degenerating regions of the Parkinson’s
disease brain.40,41 This poses an interesting question regarding
the toxicity of synucleinopathy pathways in brain regions where
metal levels are normal. In vitro evidence suggests that metal
ions interact with a-synuclein to promote oxidative stress and
neuronal death,42 however, we report here that the FUS, which
features accumulation of a-synuclein in Parkinson’s disease in
the absence cell death does not exhibit altered metal levels.
Maintenance of metal homeostasis may thus be sufficient to
mitigate cell death, despite proteinopathy. Further, no measur-
able increase in Fe within the FUS compared to control implies
that increased oxidative stress arising from the Fe/dopamine/
a-synuclein axis does not occur within this brain region.43 The
FUS has recently been established as a site of marked glial
activation in Parkinson’s disease44 which suggests that neuro-
inflammatory processes are not contributing to an increased
amount of total Fe.
Given that many transition metals pose a significant oxida-
tive threat to tissues, the proportion of free, or ‘labile’ metals
present is limited and highly regulated.45 In the healthy cell,
the majority of Fe is present in the cytoplasm as the reduced
ferric species46 and as part of a redox-silenced protein complex,
which may utilise the metal for a specific biological function
(e.g. Fe-catalysed activity of aromatic amino acid hydroxylases) or
provide a mechanism for safe storage (e.g. ferritin). For instance,
labile Fe present in a typical cell is estimated to account for
around 3–5% of total cellular iron (B1–3 mg g1), and labile Cu
in the human cortex has been empirically measured at a similar
concentration.47
Elevated Fe in the Parkinson’s disease SN has long been
associated with neurotoxicity via various mechanisms such as
oxidative,48 ferroptosis,49 and deleterious interactions between
dopamine and Fe.43,50 It has long been argued whether Fe
accumulation in the Parkinson’s disease SN is a potential upstream
cause of disease51,52 or merely an effect of inflammation.53,54
Despite this however, both inflammatory responses, and increased
intraneuronal Fe and altered intracellular Fe-regulating systems
have been implicated Fe dyshomeostasis in neuronal loss in the
PD brain. The importance of brain Fe changes in the aetiology
of Parkinson’s disease may best be demonstrated by removal
of excess levels of this metal. Iron chelation therapy using
deferiprone to lower brain iron levels has showed promise in
pilot clinical studies55 and is now in Phase IIa trials in recently-
diagnosed Parkinson’s disease patients (FAIR PARK II; Clinical-
Trials.gov identifier: NCT02655315).
Dysfunction in a range of Fe regulatory pathways have been
associated with its neuronal accumulation in Parkinson’s
disease,56 which we show here is primarily present in the
soluble tissue fraction. These changes include decreased activity of
the ferroxidase ceruloplasmin, an extracellular protein responsible
for reducing Fe(II) to Fe(III) for transferrin loading after neuronal
export,57 due to a lack of its required Cu cofactor.30 Modulation
of ceruloplasmin has been proposed as a potential therapeutic
strategy for Parkinson’s disease.58
An additional cuproprotein potentially affected by a reduction
in cytosolic Cu is the antioxidant conferring enzyme superoxide
dismutase-1 (SOD1). Recent data has demonstrated increased
SOD1 protein levels, yet a marked decrease in enzymatic activity
in the Parkinson’s disease SN,34 proposed to result due to a lack
of an essential Cu-association with this protein. Given the key
bioactive role for Cu-mediated antioxidant activity in the brain,
Cu modulation is a potential therapeutic avenue for Parkinson’s
disease,59 and the repurposed positron emission tomography
agent copper(II) diacetylbis(N(4)-methylthiosemi-carbazonato),
or CuII(atsm), has shown efficacy in transgenic and neurotoxin
mouse models of Parkinson’s disease.60
The Braak staging scale used to describe the severity of Lewy
pathology in the Parkinson’s disease brain does not necessarily
reflect the more restricted pattern of neuronal loss in this
disorder;24 nevertheless this method is considered the patho-
logical standard for assessing Parkinson’s disease progression
and severity. Braak staging refers to the progressive pattern of
synucleinopathy deposition which originates in the brainstem
and olfactory regions and spreads throughout the brain, classified
according to six distinct stages at autopsy.23 Lewy pathology is first
observed in the SN at stage III, and by stage VI it has spread
throughout the neocortex. As post mortem Parkinson’s disease
cases are typically retrieved at end-stage disease, our analysis was
limited to Braak stage V and VI cases. We did not observe any
consistent progression in the alterations in Cu or Fe levels
between the two stages, suggesting that metal dyshomeostasis
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within the Parkinson’s disease SN occurs during earlier stages of
the disease. This is consistent with reports of elevated Fe and Cu
reductions in the SN of patients with incidental Lewy body
disease,8 considered a prodromal form of Parkinson’s disease.61
A larger scale study examining metal levels in the SN and other
degenerating, and non-degenerating brain regions, fromParkinson’s
disease cases representing all six pathologically confirmed
Braak stages would assist in determining possible relationships
between metal dyshomeostasis and disease progression.
Conclusions
Although decreased Cu and elevated Fe levels in the Parkinson’s
disease SN have been observed in numerous studies over the
past few decades, we present here evidence that these changes
are primarily present within the soluble component of this
primary site of neurodegeneration. Further, no differences
between Braak staging indicates that these alterations are likely
to occur early in the disease process and are not merely a
redistribution of metals within cellular fractions. In line with
our previous studies, we postulate that disturbed levels of Fe and
Cu within the Parkinson’s disease SN results in increased
oxidative stress from excessive labile Fe, as well as an inadequate
cellular response to increased oxidative load by Cu-deficient,
dysfunctional cuproproteins. Combined, these two factors may
represent key mechanisms contributing to neuronal death, but
also practical targets for next-generation therapies.
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